1. Home
  2. TFX vs ACAD Comparison

TFX vs ACAD Comparison

Compare TFX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teleflex Incorporated

TFX

Teleflex Incorporated

HOLD

Current Price

$122.52

Market Cap

4.8B

Sector

Health Care

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.33

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFX
ACAD
Founded
1943
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.6B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
TFX
ACAD
Price
$122.52
$27.33
Analyst Decision
Hold
Buy
Analyst Count
10
23
Target Price
$139.88
$29.39
AVG Volume (30 Days)
757.6K
1.4M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
1.09%
N/A
EPS Growth
N/A
98.53
EPS
N/A
1.54
Revenue
$3,189,988,000.00
$1,047,118,000.00
Revenue This Year
$9.90
$15.16
Revenue Next Year
$10.51
$11.42
P/E Ratio
N/A
$17.26
Revenue Growth
5.42
12.69
52 Week Low
$102.58
$13.40
52 Week High
$185.94
$27.73

Technical Indicators

Market Signals
Indicator
TFX
ACAD
Relative Strength Index (RSI) 53.38 66.43
Support Level $123.66 $26.60
Resistance Level $127.88 $27.47
Average True Range (ATR) 3.89 0.84
MACD 0.38 -0.04
Stochastic Oscillator 39.53 86.87

Price Performance

Historical Comparison
TFX
ACAD

About TFX Teleflex Incorporated

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: